Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 3

Terminated

Conditions: Hormone Refractory Prostate Cancer
Castrate-Resistant Prostate Cancer

Interventions: Drug: isotonic, 0.9% sodium chloride
Drug: custirsen sodium
Drug: docetaxel
Drug: cabazitaxel
Drug: prednisone

First Posted Date: 2010-03-10

Last Posted Date: 2016-10-12

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 14

Registration Number: NCT01083615

Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Prednisone

First Posted Date: 2010-02-25

Last Posted Date: 2014-02-19

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 2728

Registration Number: NCT01075711

Locations: 🇩🇪
Merck Serono GmbH, Darmstadt, Germany, Darmstadt, Germany

Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma

Phase 2

Completed

Conditions: Hemangioma

Interventions: Drug: Prednisone
Drug: Propranolol

First Posted Date: 2010-02-19

Last Posted Date: 2014-12-02

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 50

Registration Number: NCT01072045

Locations: 🇧🇷
Instituto de Tratamento do Câncer Infantil (Pediatric Cancer Treatment Institute) - ITACI - ICr-HCFMUSP (Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Sao Paulo, Brazil

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2010-01-22

Last Posted Date: 2021-10-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT01054144

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Docetaxel and Sirolimus in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Docetaxel (Taxotere)
Drug: Sirolimus (Rapamycin)
Drug: Prednisone

First Posted Date: 2010-01-22

Last Posted Date: 2015-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 103

Registration Number: NCT01054313

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: carboplatin
Drug: RAD 001
Drug: prednisone
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2010-01-18

Last Posted Date: 2020-12-01

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01051570

Locations: 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Northshore University Health System, Evanston, Illinois, United States

and more 1 locations

Community Care for Croup (RCT)

Phase 4

Completed

Conditions: Croup

Interventions: Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2010-01-05

Last Posted Date: 2014-09-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 87

Registration Number: NCT01042145

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: VELCADE
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2009-12-30

Last Posted Date: 2014-01-13

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 164

Registration Number: NCT01040871

Locations: 🇧🇪
Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium

A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: EC-MPS
Drug: MMF
Drug: Prednisone

First Posted Date: 2009-12-17

Last Posted Date: 2015-08-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT01033864

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Phase 3

Completed

Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: doxorubicin hydrochloride
Drug: liposomal vincristine sulfate
Drug: vinorelbine tartrate
Drug: cyclophosphamide
Drug: prednisone
Drug: etoposide phosphate
Biological: filgrastim
Drug: ifosfamide

First Posted Date: 2009-12-04

Last Posted Date: 2022-04-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 166

Registration Number: NCT01026220

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States

and more 174 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy